Quale sarebbe il prezzo per Neumora Therapeutics, Inc. Common Stock (NMRA)

Il prezzo per Neumora Therapeutics, Inc. Common Stock (NMRA) è $1.35

Qual è la capitalizzazione di mercato per Neumora Therapeutics, Inc. Common Stock (NMRA)

La capitalizzazione di mercato per Neumora Therapeutics, Inc. Common Stock (NMRA) è $249.21M

Neumora Therapeutics, Inc. Common Stock (NMRA) EPS

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Anno	EPS	Cambia
Non abbastanza dati per le date fornite.

Anno

EPS

Cambia

Non abbastanza dati per le date fornite.

Azienda	EPS	Differenza di EPS	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Azienda

EPS

Differenza di EPS

Il paese